Guilin Sanjin Pharmaceutical Co Ltd
Guilin Sanjin Pharmaceutical Co., Ltd. engages in the research, production, and sale of traditional Chinese and natural medicines in China and internationally. The company offers three gold particles, Guilin watermelon frost, watermelon frost lozenges, throat clearing spray, Naomaitai capsules, vertigo tablets, Xuanyunning granules, Gejie dingchuan capsule, compound panax notoginseng stomachache … Read more
Guilin Sanjin Pharmaceutical Co Ltd (002275) - Total Liabilities
Latest total liabilities as of September 2025: CN¥1.05 Billion CNY
Based on the latest financial reports, Guilin Sanjin Pharmaceutical Co Ltd (002275) has total liabilities worth CN¥1.05 Billion CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Guilin Sanjin Pharmaceutical Co Ltd - Total Liabilities Trend (2006–2024)
This chart illustrates how Guilin Sanjin Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Guilin Sanjin Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Guilin Sanjin Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
CATARC Automotive Proving Ground Co.Ltd.
SHE:301215
|
China | CN¥575.00 Million |
|
Bumi Armada Bhd
KLSE:5210
|
Malaysia | RM2.88 Billion |
|
Esab India Limited
NSE:ESABINDIA
|
India | ₹2.20 Billion |
|
Ningbo Heli Mould Technology Co Ltd Class A
SHG:603917
|
China | CN¥390.56 Million |
|
Objective Corporation Ltd
AU:OCL
|
Australia | AU$86.59 Million |
|
Shanghai Xujiahui Commercial Co Ltd
SHE:002561
|
China | CN¥385.03 Million |
|
QC Solar (Suzhou) Co. Ltd. A
SHE:301278
|
China | CN¥528.38 Million |
Liability Composition Analysis (2006–2024)
This chart breaks down Guilin Sanjin Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.13 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.33 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Guilin Sanjin Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Guilin Sanjin Pharmaceutical Co Ltd (2006–2024)
The table below shows the annual total liabilities of Guilin Sanjin Pharmaceutical Co Ltd from 2006 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.22 Billion | +9.24% |
| 2023-12-31 | CN¥1.12 Billion | -2.82% |
| 2022-12-31 | CN¥1.15 Billion | -8.32% |
| 2021-12-31 | CN¥1.26 Billion | +36.04% |
| 2020-12-31 | CN¥923.27 Million | +53.83% |
| 2019-12-31 | CN¥600.18 Million | +0.12% |
| 2018-12-31 | CN¥599.47 Million | +4.14% |
| 2017-12-31 | CN¥575.65 Million | +29.58% |
| 2016-12-31 | CN¥444.26 Million | +6.64% |
| 2015-12-31 | CN¥416.59 Million | -10.04% |
| 2014-12-31 | CN¥463.07 Million | -4.74% |
| 2013-12-31 | CN¥486.11 Million | +19.36% |
| 2012-12-31 | CN¥407.26 Million | +86.67% |
| 2011-12-31 | CN¥218.18 Million | +20.23% |
| 2010-12-31 | CN¥181.47 Million | -34.96% |
| 2009-12-31 | CN¥279.00 Million | -26.32% |
| 2008-12-31 | CN¥378.65 Million | +8.32% |
| 2007-12-31 | CN¥349.58 Million | +70.96% |
| 2006-12-31 | CN¥204.48 Million | -- |